LATE NEWS: Senate clears MDUFMA (Medical Device User Fee and Modernization Act) technical corrections:
This article was originally published in Clinica
Executive Summary
Legislation making technical and clarifying corrections to the Medical Device User Fee And Modernization Act (MDUFMA) cleared the US Senate on November 25 2003. The bill, S 1881, amends a component of the third-party inspection programme that if unchanged would have rendered the programme inoperable. Previous language required companies to certify that foreign countries recognise an FDA inspection and certify that they market their products in a foreign country that recognises the third-party inspector. The correction allows companies to meet one or both requirements. The legislation also creates an 18-month moratorium on the implementation of Section 301 of MDUFMA, requiring all manufacturers to place their name or brand on their device, if feasible. The US House is expected to pass the technical bill by a voice vote when lawmakers return in mid-December to wrap up the last remaining spending bills.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.